Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
PTX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume766.17K
Average Volume (3M)690.15K
Market Cap
AU$67.30M
Enterprise ValueAU$63.54M
Total Cash (Recent Filing)AU$6.93M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthMeaningful top-line expansion (≈44% YoY) signals improving commercial traction or successful licensing/partnership progress and supports longer-term scaling of R&D and operations. Sustainable revenue trends increase optionality for funding, de-risking future program advancement and commercialization plans.
Low LeverageVery low debt reduces refinancing and interest-rate risk and preserves financial flexibility during multi-year clinical development cycles. A conservative capital structure lets management prioritize R&D spending or selective partnering without immediate debt-service constraints, a durable advantage for biotech development timelines.
Pipeline FocusA portfolio combining CAR-T cell therapies and precision oncology small molecules aligns with persistent structural demand in oncology and high-barrier niches. This diversified R&D approach can generate multiple value pathways (licensing, partnerships, approvals) and supports long-term market relevance despite clinical risk.
Bears Say
Negative Cash FlowConsistent negative operating and free cash flow, with worsening FCF, creates structural dependence on external capital. Over 2–6 months this increases fundraising risk, potential dilution, and constrains discretionary R&D or commercialization spends, making long-term program continuity contingent on successful financing.
Persistent LossesSustained operating losses and negative net income indicate the business has not reached profitability or break-even, limiting retained-earnings funding for growth. This persistent unprofitability pressures returns on capital and increases reliance on equity or partner funding, a durable headwind until commercial scale or positive operating leverage occurs.
Tiny Employee BaseA three-person headcount signals limited internal capacity to manage complex clinical programs, regulatory filings, and commercialization tasks. This structural constraint elevates execution risk, increases dependence on CROs/partners, and can slow program timelines or governance oversight over multi-year development cycles.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$67.30M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 189 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-49.72%
Trailing 12-Months
Asset Growth
-28.59%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Chimeric Therapeutics Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---